Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | MIF | P14174 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | IDO1 | P14902 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7017010 | 0.85 | ALDH1A1 (0.72) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL5537126 | 0.81 | MAPK1 (0.72) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL904819 | 0.81 | MAPK1 (0.72) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL10915913 | 0.81 | MAPK1 (0.72) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL12124412 | 0.81 | MAPK1 (0.72) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL2947194 | 0.80 | HPGD (0.73) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL14198763 | 0.79 | MAPK1 (0.70) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL4414345 | 0.79 | HPGD (1.00) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL13995838 | 0.79 | HPGD (0.71) | MAPK1HPGDTSHRUSP2ALDH1A1 | |
| SCHEMBL4910314 | 0.79 | MAPK1 (0.64) | MAPK1HPGDTSHRUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| US-4518781-A | Process for the preparation of 3-hydroxymethyl-6-chlorobenzoxazolone | RHONE-POULENC AGROCHIMIE (FR) | 1985-05-21 | — | — | US | disclosed |
| US-4435577-A | Process for the preparation of chlorinated derivatives of benzoxazolones | RHONE-POULENC AGROCHIMIE (FR) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | MAPK1 3798/4885HPGD 472/4885TSHR 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.